[Recent topics on new biological agents for treatment of rheumatoid arthritis].
Saito
Kazuyoshi
K
Tanaka
Yoshiya
Y
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000954:Antigens, Surface; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D001402:B-Lymphocytes; D016207:Cytokines; D004359:Drug Therapy, Combination; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069283:Rituximab; D013601:T-Lymphocytes
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000954:Antigens, Surface; D018501:Antirheumatic Agents; D016207:Cytokines; D018796:Immunoconjugates; D000069283:Rituximab; D000069594:Abatacept; C533411:ocrelizumab; C527517:ofatumumab; D008727:Methotrexate